Brooke Griffin
Overview
Explore the profile of Brooke Griffin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
209
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papp N, Panicker J, Rubino J, Pais G, Czechowicz A, Prozialeck W, et al.
Pharmaceutics
. 2022 Jun;
14(6).
PMID: 35745726
Drugs can be toxic to the fetus depending on the amount that permeates across the maternal-fetal barrier. One way to limit the amount which penetrates this barrier is to increase...
2.
Avedissian S, Pais G, Pham M, Liu J, Chang J, Hlukhenka K, et al.
Antimicrob Agents Chemother
. 2022 Apr;
66(5):e0005622.
PMID: 35446134
Vancomycin usage is often unavoidable in pregnant patients; however, literature suggests vancomycin can cross the placental barrier and reach the fetus. Understanding the mass transit of vancomycin to the fetus...
3.
Gould A, Winders H, Stover K, Bookstaver P, Griffin B, Bland C, et al.
Drugs Context
. 2021 Oct;
10.
PMID: 34603460
This review is a comprehensive summary of treatment options for pregnant patients with less common bacterial, fungal, and viral infections. It offers guidance to clinicians based on the most recently...
4.
Philip S, Griffin B
JAAPA
. 2021 Jul;
34(8):19-20.
PMID: 34320536
New clinical studies indicate that buprenorphine can be a promising alternative to methadone for treating opioid use disorder (OUD) in pregnant women. Various benefits for the mother have been identified...
5.
Caruso K, Griffin B, Vest K, Harpe S
Innov Pharm
. 2021 May;
9(2):1-6.
PMID: 34007693
Introduction: Clinical presentation and treatment in many disease states vary due to sex- and gender-differences. Sex-related pharmacokinetic differences are particularly important for pharmacists. The Accreditation Council for Pharmacy Education (ACPE)...
6.
Stone R, Griffin B, Fusco R, Vest K, Tran T, Gross S
J Clin Pharmacol
. 2020 Dec;
60 Suppl 2:S63-S73.
PMID: 33274509
Maternal opioid use disorder increased > 4-fold from 1999 to 2014 and is associated with poor maternal and fetal outcomes. Women with opioid use disorder are at 2 to 3...
7.
Tong I, Griffin B, Trott J, Romano M, Buros Stein A, Madsen T
J Womens Health (Larchmt)
. 2020 Nov;
30(11):1616-1625.
PMID: 33252297
Sex and gender, two important factors affecting health care, should be routinely taken into consideration in clinical practice. Members of the Sex and Gender Health Collaborative Scholarship Committee reviewed clinical...
8.
Lynch S, Griffin B, Stewart-Lynch A, Vest K
Pharmacy (Basel)
. 2020 Aug;
8(3).
PMID: 32824468
Several states now permit pharmacists to prescribe hormonal contraception. Consequently, some schools of pharmacy now incorporate activities intending to prepare students to offer this service. This study aimed to assess...
9.
Kooner M, Joseph H, Griffin B, Lynch S, Vest K, Stewart-Lynch A, et al.
J Am Pharm Assoc (2003)
. 2020 Mar;
60(5):e34-e39.
PMID: 32144081
Objectives: Empowering pharmacists to prescribe contraceptives could help alleviate barriers such as the accessibility of medical centers and the availability, inconvenience, and cost of appointments. Several states have enacted legislation...
10.
Stone R, Rafie S, Griffin B, Shealy K, Buros Stein A
Curr Pharm Teach Learn
. 2019 Dec;
12(1):27-34.
PMID: 31843161
Introduction: Our objectives were to describe pharmacist perceptions of training and preparation to prescribe hormonal contraception (HC), identify training gaps, and elicit preferred training methods. Methods: In this cross-sectional survey,...